oh-myyy-ribbon
This illustration picture shows a saliva collection kit for DNA testing displayed in Washington DC on December 19, 2018. - Between 2015 and 2018, sales of DNA test kits boomed in the United States and allowed websites to build a critical mass of DNA profiles. The four DNA websites that offer match services -- Ancestry, 23andMe, Family Tree DNA, My Heritage -- today have so many users that it is rare for someone not to find at least one distant relative. (Photo by Eric BARADAT / AFP) (Photo credit should read ERIC BARADAT/AFP/Getty Images)

Genetic testing company 23andMe has just gotten FDA approval to sell a test for hereditary colorectal cancer syndrome directly to their consumers.

The test examines three genetic variants of Ashkenazi Jewish ancestry that have indicated a correlation to the cancer syndrome. It's the second time that 23andMe has been approved for a cancer test based on genetic mutations, with the first being a test for the BRCA gene which can act as a litmus test for the likelihood of developing breast cancer.

Keep reading... Show less
MDMA, or Ecstasy pills, and powder and orange juice chaser. (Photo by Steve Liss/The LIFE Images Collection/Getty Images)

It is known by many names in popular culture: “hug drug,” “love drug,” “dance drug,” “ecstasy,” “XTC” and “Molly” — along with its scientific designation: MDMA. Now, the Food and Drug Administration (FDA) has bestowed an additional moniker: “breakthrough therapy.”

The FDA has announced that it is considering MDMA as a therapy to treat veterans with PTSD.

Keep reading... Show less

Migraines affect millions of Americans. Although many medications can treat migraines once they occur, there has yet to be to be an effective FDA-approved medication that actually prevents the onset of migraines.

On May 17th, the first medication designed to prevent migraines was approved by the Food and Drug Administration. Four more preventative migraine medications are currently in the pipeline.

Keep reading... Show less

For the first time, a federal advisory committee has recommended that the Food and Drug Association (FDA) vote to approve a prescription cannabidiol medicine. The medication, known as Epidiolex, is a form of cannabidiol (CBD), which is a cannabis derivative. According to a report by NBC News, approval of the medication would be limited to treating seizures caused by Lennox-Gastaut syndrome and Dravet syndrome in patients aged 2 and older. Although the FDA has indicated that it would vote in favor or approval, the medication has only received such a recommendation from the aforementioned federal advisory committee after a unanimous vote. The FDA is expected to make a final decision by June.

As previously reported in December, Dravet syndrome has already been treated in legal states by cannabis-oil derivatives. A study in the New England Journal of Medicine indicated that out of 120 children, half experienced reduction of the frequency of seizures when treated with medicinal cannabis-based products.

Keep reading... Show less

Good news, health-conscious readers. You can now buy water here in the United States that is gluten-free, non-GMO and even organic. Just swing over to the website for “Clara Gluten-Free Water” if it’s not carried in your local health food store. This water is meant for “health-conscious individuals worried about the source” of their water, and is “guaranteed gluten-free with a surprisingly fresh taste on the palate.”

There’s just one problem. There’s no such thing as water with gluten. (Unless you’re talking about bottling the water you boil your pasta in.) There is also no such thing as genetically-modified water or non-organic water.

Keep reading... Show less

[DIGEST: NPR, NY Times]

The Food and Drug Administration advisory committee recommended unanimously that the drug-regulating agency approve a “living drug” approach for children and young adults who are diagnosed with a common type of leukemia.

Keep reading... Show less

[DIGEST: New York Times, NBC]

Late last month, the Federal Drug Administration approved a new drug to treat multiple sclerosis. The drug, called ocrelizumab, is the first FDA-approved drug to treat primary progressive MS, a severe form of multiple sclerosis. It is also approved to help the more common form of the disease known as relapse-remitting.

Keep reading... Show less